APM
RVMD icon

Avidity Partners Management’s Revolution Medicines RVMD Stock Holding History

Avidity Partners Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$1.46M – 56
2026
Q1 		$1.46M Buy
+15,000
New +$1.51M 0.3% 30
2025
Q3 		– Sell
-228,600
Closed -$8.41M – 60
2025
Q2 		$8.41M Buy
228,600
+15,600
+7% +$599K 1.68% 23
2025
Q1 		$7.53M Sell
213,000
-233,200
-52% -$9.47M 1.44% 28
2024
Q4 		$19.5M Sell
446,200
-343,800
-44% -$17.4M 1.92% 23
2024
Q3 		$35.8M Buy
790,000
+35,000
+5% +$1.52M 1.83% 22
2024
Q2 		$29.3M Buy
755,000
+120,000
+19% +$4.49M 1.25% 33
2024
Q1 		$20.5M Buy
635,000
+575,000
+958% +$17M 0.66% 50
2023
Q4 		$1.72M Sell
60,000
-597,200
-91% -$14.4M 0.06% 70
2023
Q3 		$18.2M Sell
657,200
-417,800
-39% -$12.4M 0.73% 50
2023
Q2 		$28.8M Sell
1,075,000
-269,800
-20% -$6.62M 1% 40
2023
Q1 		$29.1M Sell
1,344,800
-1,130,200
-46% -$27.8M 0.97% 38
2022
Q4 		$59M Buy
2,475,000
+153,800
+7% +$3.27M 1.28% 27
2022
Q3 		$45.8M Buy
2,321,200
+996,200
+75% +$21.9M 0.93% 36
2022
Q2 		$25.8M Buy
+1,325,000
New +$25.8M 0.59% 37

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Avidity Partners Management's RVMD Position: Q2 2026 in Review

Avidity Partners Management sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 15,000 shares — an estimated $1.46M sold.

Avidity Partners Management first reported a position in RVMD in Q2 2022 and held it in 14 quarters. The position peaked at $59M in Q4 2022. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Avidity Partners Management reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Avidity Partners Management sold 15,000 Revolution Medicines shares in Q2 2026, an estimated $1.46M.
  • Avidity Partners Management first reported a position in Revolution Medicines in Q2 2022 and held it in 14 quarters.
  • Avidity Partners Management's Revolution Medicines position peaked at $59M in Q4 2022.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.